Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 3/2003

01-03-2003 | Therapy in Practice

Treatment of Pruritus Associated with Systemic Disorders in the Elderly

A Review of the Role of New Therapies

Authors: Dr Ann Lonsdale-Eccles, Andrew J. Carmichael

Published in: Drugs & Aging | Issue 3/2003

Login to get access

Abstract

Generalised pruritus is common in the elderly. Idiopathic ‘senile pruritus’ is a diagnosis of exclusion, and an underlying systemic disorder should be sought. Thyroid disease, haematological malignancy, iron deficiency, cholestasis or renal impairment may be responsible for pruritus. Rarely pruritus may occur after cerebral infarction or as a paraneoplastic phenomenon.
The mechanisms of pruritus are poorly understood. In systemic disorders, correction of the underlying disorder alleviates itch. However, when this cannot be achieved, a symptomatic approach is required.
Response to treatment varies enormously and an empirical approach is often required. Topical applications are available to soothe the skin and bandaging techniques may improve their efficacy. A number of more targeted treatments are available for renal and cholestatic pruritus. Novel therapies such as thalidomide, opioid antagonists, ondansetron and phototherapy with ultraviolet (UV)-B radiation are now being used.
Treatment of pruritus needs to be individualised, and the elderly present a particular challenge. Adequate delivery of simple emollients may be impossible because of physical impairment The elderly are more vulnerable to the adverse effects of treatments, comorbidities may alter the pharmacokinetics of drug metabolism and polypharmacy increases the likelihood of adverse drug interactions. Cognitive impairment can lead to poor compliance with treatment.
The patient’s general health, the severity of symptoms and the adverse effects of treatment all need to be considered. Most treatments are of benefit only to some patients; others derive only marginal improvement. Many of the newer treatments are unlicensed for pruritus and should preferably be administered under specialist supervision.
We review the literature concerning the treatment of itch associated with systemic diseases, with particular emphasis on issues relevant to the elderly. Pruritus is a difficult symptom to treat. However, it is hoped that research into the mechanisms underlying the pruritus of systemic disease will allow a better understanding so that we should be able to look forward to more specific and effective therapies in the future.
Literature
1.
Lidstone V, Thorns A. Pruritus in cancer patients. Cancer Treat Rev 2001; 27(5): 305–12PubMed
2.
Greaves MW. Itching — research has barely scratched the surface. N Engl J Med 1992; 326(15): 1016–7PubMed
3.
Denman ST. A review of pruritus. J Am Acad Dermatol 1986; 14(3): 375–92PubMed
4.
Potts RO, Buras Jr EM, Chrisman Jr DA. Changes with age in the moisture content of human skin. J Invest Dermatol 1984; 82(1): 97–100PubMed
5.
Kantor GR, Lookingbill DP. Generalized pruritus and systemic disease. J Am Acad Dermatol 1983; 9(3): 375–82PubMed
6.
Dykes PJ, Marks R. An appraisal of the methods used in the assessment of atrophy from topical corticosteroids. Br J Dermatol 1979; 101(5): 599–609PubMed
7.
Reitamo S, Rissanen J, Remitz A, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol 1998; 111(3): 396–8PubMed
8.
Aioardi C, Dost FH. Menthol and menthol-containing external remedies. International symposium on menthol and menthol-containing external remedies; use, mode of effect and tolerance in children. In: Do Fh, Leiber B, editors. International Symposium; 1966 April; Paris: Stuttgart, George Thieme Verlag, 1967
9.
Bromm B, Scharein E, Darsow U, et al. Effects of menthol and cold on histamine-induced itch and skin reactions in man. Neurosci Lett 1995; 187(3): 157–60PubMed
10.
Hagermark O, Wahlgren CF. Treatment of itch. Semin Dermatol 1995; 14(4): 320–5PubMed
11.
Smith EB, King CA, Baker MD. Crotamiton lotion in pruritus. Int J Dermatol 1984; 23(10): 684–5PubMed
12.
Doxepin cream for eczema?Drug Ther Bull 2000; 38(4): 31–2
13.
Greiding L, Moreno P. Doxepin incorporated into a dermatologic cream: an assessment of both doxepin antipruritic action and doxepin action as an inhibitor of papules, in allergen and histamine-caused pruritus. Allergol Immunopathol (Madr) 1999; 27(5): 265–70
14.
Drake LA, Millikan LE. The antipruritic effect of 5% doxepin cream in patients with eczematous dermatitis. Doxepin Study Group. Arch Dermatol 1995; 131(12): 1403–8PubMed
15.
Drake LA, Fallon JD, Sober A. Relief of pruritus in patients with atopic dermatitis after treatment with topical doxepin cream. The Doxepin Study Group. J Am Acad Dermatol 1994; 31(4): 613–6PubMed
16.
Tonnesen MG. Pruritus. In: Fitzpatrick TB, Eisen AZ, Wolff K, editors. Dermatology in general medicine. 2nd ed. New York: McGraw-Hill, 1979: 32–4
17.
Isaacs NJ, Ertel NH. Urticaria and pruritus: uncommon manifestations of hyperthyroidism. J Allergy Clin Immunol 1971; 48(2): 73–81PubMed
18.
Barnes HM, Sarkany I, Calnan CD. Pruritus and thyrotoxicosis. Trans St Johns Hosp Dermatol Soc 1974; 60(1): 59–62PubMed
19.
Carmichael AJ, McHugh MM, Martin AM, et al. Serological markers of renal itch in patients receiving long term haemodialysis. Br Med J (Clin Res Ed) 1988; 296(6636): 1575
20.
Blachley JD, Blankenship DM, Menter A, et al. Uremic pruritus: skin divalent ion content and response to ultraviolet phototherapy. Am J Kidney Dis 1985; 5(5): 237–41PubMed
21.
Winkelmann RK. Pharmacologic control of pruritus. Med Clin North Am 1982; 66(5): 1119–33PubMed
22.
Kleeman CR, Massry SG, Popovtzer MM, et al. The disappearance of intractable pruritus after parathyroidectomy in uremic patients with secondary hyperparathyroidism. Trans Assoc Am Physicians 1968; 81: 203–12PubMed
23.
Massry SG, Popovtzer MM, Coburn JW, et al. Intractable pruritus as a manifestation of secondary hyperparathyroidism in uremia. Disappearance of itching after subtotal parathyroidectomy. N Engl J Med 1968; 279(13): 697–700PubMed
24.
Neilly JB, Martin A, Simpson N, et al. Pruritus in diabetes mellitus: investigation of prevalence and correlation with diabetes control. Diabetes Care 1986; 9: 273–5PubMed
25.
Staubli M. Pruritus — a little known iron-deficiency symptom [in German]. Schweiz Med Wochenschr 1981; 111(38): 1394–8PubMed
26.
Oral iron. In: Mehta DK, editor. British National Formulary. 43th ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2002: 437
27.
Gilchrest BA. Pruritus: pathogenesis, therapy, and significance in systemic disease states. Arch Intern Med 1982; 142(1): 101–5PubMed
28.
Wasserman LR. The treatment of polycythemia vera. Semin Hematol 1976; 13(1): 57–78PubMed
29.
Archer CB, Camp RD, Greaves MW. Polycythaemia vera can present with aquagenic pruritus. Lancet 1988; 1(8600): 1451PubMed
30.
Muller EW, de Wolf JT, Egger R, et al. Long-term treatment with interferon-alpha 2b for severe pruritus in patients with polycythaemia vera. Br J Haematol 1995; 89(2): 313–8PubMed
31.
Salem HH, Van der Weyden MB, Young IF, et al. Pruritus and severe iron deficiency in polycythaemia vera. Br Med J (Clin Res Ed) 1982; 285(6335): 91–2
32.
Fjellner B, Hagermark O. Pruritus in polycythemia vera: treatment with aspirin and possibility of platelet involvement. Acta Derm Venereol 1979; 59(6): 505–12PubMed
33.
Weick JK, Donovan PB, Najean Y, et al. The use of cimetidine for the treatment of pruritus in polycythemia vera. Arch Intern Med 1982; 142(2): 241–2PubMed
34.
Kolodny L, Horstman LL, Sevin BU, et al. Danazol relieves refractory pruritus associated with myeloproliferative disorders and other diseases. Am J Hematol 1996; 51(2): 112–6PubMed
35.
Randi ML, Luzzatto G, Fabris F. Danazol in refractory pruritus of myeloproliferative disorders. Am J Hematol 1997; 54(2): 172–3PubMed
36.
Chanarin I, Szur L. Relief of intractable pruritus in polycythaemia rubra vera with cholestyramine [letter]. Br J Haematol 1975; 29(4): 669–70PubMed
37.
Steinman HK, Greaves MW. Aquagenic pruritus. J Am Acad Dermatol 1985; 13(1): 91–6PubMed
38.
Jeanmougin M, Rain JD, Najean Y. Efficacy of photochemotherapy on severe pruritus in polycythemia vera. Ann Hematol 1996; 73(2): 91–3PubMed
39.
Baldo A, Monfrecola G. Narrowband (TL-01) ultraviolet B phototherapy for pruritus in polycythaemia vera. Br J Dermatol 2002; 147(5): 979–81PubMed
40.
Gaudin P, Rozand Y, Fauconnier J, et al. Rheumatic manifestations at presentation of Hodgkin’s disease and non-Hodgkin’s malignant lymphoma: a national survey of one hundred fortysix patients. Rev Rhum Engl Ed 1995; 62(5): 365–75PubMed
41.
Alexander LL. Pruritus and Hodgkin’s disease. JAMA 1979; 241(24): 2598–9PubMed
42.
Feiner AS, Mahmood T, Wallner SF. Prognostic importance of pruritus in Hodgkin’s disease. JAMA 1978; 240(25): 2738–40PubMed
43.
Gobbi PG, Attardo-Parrinello G, Lattanzio G, et al. Severe pruritus should be a B-symptom in Hodgkin’s disease. Cancer 1983; 51(10): 1934–6PubMed
44.
Gobbi PG, Cavalli C, Gendarini A, et al. Reevaluation of prognostic significance of symptoms in Hodgkin’s disease. Cancer 1985; 56(12): 2874–80PubMed
45.
Young Jr AW, Sweeney EW, David DS, et al. Dermatologic evaluation of pruritus in patients on hemodialysis. N Y State J Med 1973; 73(22): 2670–4PubMed
46.
Gilchrest BA, Stern RS, Steinman TI, et al. Clinical features of pruritus among patients undergoing maintenance hemodialysis. Arch Dermatol 1982; 118(3): 154–6PubMed
47.
Bencini PL, Montagnino G, Citterio A, et al. Cutaneous abnormalities in uremic patients. Nephron 1985; 40(3): 316–21PubMed
48.
Southi P, Commens C. Pruritus in dialysis patients. Med J Aust 1987; 146(7): 397, 400PubMed
49.
Matsumoto M, Ichimaru K, Horie A. Pruritus and mast cell proliferation of the skin in end stage renal failure. Clin Nephrol 1985; 23(6): 285–8PubMed
50.
Stahle-Backdahl M. Uremic pruritus. Clinical and experimental studies. Acta Derm Venereol Suppl 1989; 145: 1–38
51.
Ponticelli C, Bencini PL. Uremic pruritus: a review. Nephron 1992; 60(1): 1–5PubMed
52.
Duo LJ. Electrical needle therapy of uremic pruritus. Nephron 1987; 47(3): 179–83PubMed
53.
Yatzidis H, Digenis P, Tountas C. Heparin treatment of uremic itching. JAMA 1972; 222(9): 1183PubMed
54.
Fishman SM, Caneris OA, Stojanovic MP, et al. Intravenous lidocaine for treatment-resistant pruritus. Am J Med 1997; 102(6): 584–5PubMed
55.
Watson WC. Intravenous lignocaine for relief of intractable itch. Lancet 1973; 1(7796): 211PubMed
56.
Tapia L, Cheigh JS, David DS, et al. Pruritus in dialysis patients treated with parenteral lidocaine. N Engl J Med 1977; 296(5): 261–2PubMed
57.
Masi CM, Cohen EP. Dialysis efficacy and itching in renal failure. Nephron 1992; 62(3): 257–61PubMed
58.
Hiroshige K, Kabashima N, Takasugi M, et al. Optimal dialysis improves uremic pruritus. Am J Kidney Dis 1995; 25(3): 413–9PubMed
59.
Kyriazis J, Glotsos J. Dialysate calcium concentration of </=1.25 mmol/l: is it effective in suppressing uremic pruritus? Nephron 2000; 84(1): 85–6PubMed
60.
Schwartz IF, Iaina A. Uraemic pruritus. Nephrol Dial Transplant 1999; 14(4): 834–9PubMed
61.
Pauli-Magnus C, Mikus G, Alscher DM, et al. Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study. J Am Soc Nephrol 2000; 11(3): 514–9PubMed
62.
Morton CA, Lafferty M, Hau C, et al. Pruritus and skin hydration during dialysis. Nephrol Dial Transplant 1996; 11(10): 2031–6PubMed
63.
De Marchi S, Cecchin E, Villalta D, et al. Relief of pruritus and decreases in plasma histamine concentrations during erythropoietin therapy in patients with uremia. N Engl J Med 1992; 326(15): 969–74PubMed
64.
Balaskas EV, Uldall RP. Erythropoietin treatment does not improve uremic pruritus. Perit Dial Int 1992; 12(3): 330–1PubMed
65.
Tan JK, Haberman HF, Coldman AJ. Identifying effective treatments for uremic pruritus. J Am Acad Dermatol 1991; 25 (5 Pt 1): 811–8PubMed
66.
Gilchrest BA, Rowe JW, Brown RS, et al. Ultraviolet phototherapy of uremic pruritus. Long-term results and possible mechanism of action. Ann Intern Med 1979; 91(1): 17–21PubMed
67.
Slaper H, Schothorst AA, van der Leun JC. Risk evaluation of UVB therapy for psoriasis: comparison of calculated risk for UVB therapy and observed risk in PUVA-treated patients. Photodermatol 1986; 3(5): 271–83PubMed
68.
Taylor R, Taylor AE, Diffey BL, et al. A placebo-controlled trial of UV-A phototherapy for the treatment of uraemic pruritus. Nephron 1983; 33(1): 14–6PubMed
69.
Simpson NB, Davison AM. Ultraviolet phototherapy for uraemic pruritus. Lancet 1981; 1(8223): 781PubMed
70.
Spiro JG, Scott S, MacMillan J, et al. Treatment of uremic pruritus with blue light. Photodermatol 1985; 2(5): 319–21PubMed
71.
Silverberg DS, Iaina A, Reisin E, et al. Cholestyramine in uraemic pruritus. Br Med J 1977; 1(6063): 752–3PubMed
72.
van Leusen R, Kutsch Lojenga JC, Ruben A. Is cholestyramine helpful in uraemic pruritus? Br Med J 1978; 1(6117): 918–9PubMed
73.
Wrong OM. Cholestyramine in uraemic pruritus. Br Med J 1977; 1(6077): 1662PubMed
74.
Pederson JA, Matter BJ, Czerwinski AW, et al. Relief of idiopathic generalized pruritus in dialysis patients treated with activated oral charcoal. Ann Intern Med 1980; 93(3): 446–8PubMed
75.
Giovannetti S, Barsotti G, Cupisti A, et al. Oral activated charcoal in patients with uremic pruritus. Nephron 1995; 70(2): 193–6PubMed
76.
Mettang T, Fischer FP, Dollenbacher U, et al. Uraemic pruritus is not related to beta-endorphin serum levels in haemodialysis patients. Nephrol Dial Transplant 1998; 13(1): 231–2PubMed
77.
Hwang JC, Hsu KT, Tsai HC, et al. Serum endorphin levels in uremic patients under maintenance hemodialysis. Taiwan Yi Xue Hui Za Zhi 1989; 88(4): 360–5PubMed
78.
Peer G, Kivity S, Agami O, et al. Randomised crossover trial of naltrexone in uraemic pruritus. Lancet 1996; 348(9041): 1552–4PubMed
79.
Kerr PG, Argiles A, Mion C. Whole blood serotonin levels are markedly elevated in patients on dialytic therapy. Am J Nephrol 1992; 12(1–2): 14–8PubMed
80.
Balaskas EV, Bamihas GI, Karamouzis M, et al. Histamine and serotonin in uremic pruritus: effect of ondansetron in CAPD-pruritic patients. Nephron 1998; 78(4): 395–402PubMed
81.
Ashmore SD, Jones CH, Newstead CG, et al. Ondansetron therapy for uremic pruritus in hemodialysis patients. Am J Kidney Dis 2000; 35(5): 827–31PubMed
82.
Murphy M, Reaich D, Finn P, et al. A randomised, placebo-controlled, double-blind trial of ondansetron in renal itch. Br J Dermatol 2001; 145: 34–5
83.
Breneman DL, Cardone JS, Blumsack RF, et al. Topical capsaicin for treatment of hemodialysis-related pruritus. J Am Acad Dermatol 1992; 26(1): 91–4PubMed
84.
Cho YL, Liu HN, Huang TP, et al. Uremic pruritus: roles of parathyroid hormone and substance P. J Am Acad Dermatol 1997; 36(4): 538–43PubMed
85.
Tarng DC, Cho YL, Liu HN, et al. Hemodialysis-related pruritus: a double-blind, placebo-controlled, crossover study of capsaicin 0.025% cream. Nephron 1996; 72(4): 617–22PubMed
86.
Neiman RS, Bischel MD, Lukes RJ. Uraemia and mast-cell proliferation. Lancet 1972; 1(7757): 959PubMed
87.
Stockenhuber F, Kurz RW, Serti K, et al. Increased plasma histamine levels in uraemic pruritus. Clin Sci (Colch) 1990; 79(5): 477–82
88.
Mettang T, Fritz P, Weber J, et al. Uremic pruritus in patients on hemodialysis or continuous ambulatory peritoneal dialysis (CAPD). The role of plasma histamine and skin mast cells. Clin Nephrol 1990; 34(3): 136–41PubMed
89.
Klein LR, Klein JB, Hanno R, et al. Cutaneous mast cell quantity in pruritic and nonpruritic hemodialysis patients. Int J Dermatol 1988; 27(8): 557–9PubMed
90.
Silva SR, Viana PC, Lugon NV, et al. Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial. Nephron 1994; 67(3): 270–3PubMed
91.
Powell RJ, Gardner-Medwin JM. Guideline for the clinical use and dispensing of thalidomide. Postgrad Med J 1994; 70(830): 901–4PubMed
92.
Ghent CN. Cholestatic pruritus. In: Bernhard JD, editor. Itch, mechanisms, and management of pruritus. New York: McGraw-Hill, 1994: 229–42
93.
Ahrens EH, Payne MA, Kunkel HG, et al. Primary biliary cirrhosis. Medicine 1950; 29: 299–364PubMed
94.
Bartholomew TC, Summerfield JA, Billing BH, et al. Bile acid profiles of human serum and skin interstitial fluid and their relationship to pruritus studied by gas chromatography-mass spectrometry. Clin Sci (Colch) 1982; 63(1): 65–73
95.
Jones EA, Bergasa NV. The pruritus of cholestasis. Hepatology 1999; 29(4): 1003–6PubMed
96.
Rupp N. Indications and results of percutaneous transhepatic bile-duct drainage [in German]. Chirurg 1979; 50(4): 233–8PubMed
97.
Bergasa NV, Jones EA. Management of the pruritus of cholestasis: potential role of opiate antagonists. Am J Gastroenterol 1991; 86(10): 1404–12PubMed
98.
Frezza M, Surrenti C, Manzillo G, et al. Oral S-adenosylmethionine in the symptomatic treatment of intrahepatic cholestasis: a double-blind, placebo-controlled study. Gastroenterology 1990; 99(1): 211–5PubMed
99.
Metze D, Reimann S, Beissert S, et al. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. J Am Acad Dermatol 1999; 41(4): 533–9PubMed
100.
Thornton JR, Losowsky MS. Opioid peptides and primary biliary cirrhosis. BMJ 1988; 297(6662): 1501–4PubMed
101.
Bergasa NV, Ailing DW, Vergalla J, et al. Cholestasis in the male rat is associated with naloxone-reversible antinociception. J Hepatol 1994; 20(1): 85–90PubMed
102.
Bergasa NV, Talbot TL, Ailing DW, et al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 1992; 102(2): 544–9PubMed
103.
Bergasa NV, Ailing DW, Talbot TL, et al. Effects of naloxone infusions in patients with the pruritus of cholestasis: a double-blind, randomized, controlled trial. Ann Intern Med 1995; 123(3): 161–7PubMed
104.
Bergasa NV, Schmitt JM, Talbot TL, et al. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology 1998; 27(3): 679–84PubMed
105.
Bergasa NV, Ailing DW, Talbot TL, et al. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study. J Am Acad Dermatol 1999; 41 (3 Pt 1): 431–4PubMed
106.
Wolfhagen FH, Sternieri E, Hop WC, et al. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 1997; 113(4): 1264–9PubMed
107.
Carson KL, Tran TT, Cotton P, et al. Pilot study of the use of naltrexone to treat the severe pruritus of cholestatic liver disease. Am J Gastroenterol 1996; 91(5): 1022–3PubMed
108.
Jones EA, Dekker LR. Florid opioid withdrawal-like reaction precipitated by naltrexone in a patient with chronic cholestasis. Gastroenterology 2000; 118(2): 431–2PubMed
109.
Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology 1988; 94(2): 488–93PubMed
110.
Bloomer JR, Boyer JL. Phenobarbital effects in cholestatic liver diseases. Ann Intern Med 1975; 82(3): 310–7PubMed
111.
Turner IB, Rawlins MD, Wood P, et al. Flumecinol for the treatment of pruritus associated with primary biliary cirrhosis. Aliment Pharmacol Ther 1994; 8(3): 337–42PubMed
112.
Hoensch HP, Balzer K, Dylewizc P, et al. Effect of rifampicin treatment on hepatic drug metabolism and serum bile acids in patients with primary biliary cirrhosis. Eur J Clin Pharmacol 1985; 28(4): 475–7PubMed
113.
Cynamon HA, Andres JM, Iafrate RP. Rifampin relieves pruritus in children with cholestatic liver disease. Gastroenterology 1990; 98(4): 1013–6PubMed
114.
Woolf GM, Reynolds TB. Failure of rifampin to relieve pruritus in chronic liver disease. J Clin Gastroenterol 1990; 12(2): 174–7PubMed
115.
Bachs L, Pares A, Elena M, et al. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet 1989; 1(8638): 574–6PubMed
116.
Kreek MJ, Garfield JW, Gutjahr CL, et al. Rifampin-induced methadone withdrawal. N Engl J Med 1976; 294(20): 1104–6PubMed
117.
Prince MI, Jones DE. Primary biliary cirrhosis: new perspectives in diagnosis and treatment. Postgrad Med J 2000; 76(894): 199–206PubMed
118.
Schworer H, Hartmann H, Ramadori G. Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron. Pain 1995; 61(1): 33–7PubMed
119.
Muller C, Pongratz S, Pidlich J, et al. Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol 1998; 10(10): 865–70PubMed
120.
Larijani GE, Goldberg ME, Rogers KH. Treatment of opioid-induced pruritus with ondansetron: report of four patients. Pharmacotherapy 1996; 16(5): 958–60PubMed
121.
Crighton IM, Hobbs GJ, Reid MF. Ondansetron for the treatment of pruritus after spinal opioids. Anaesthesia 1996; 51(2): 199–200PubMed
122.
Borgeat A, Wilder-Smith OH, Mentha G. Subhypnotic doses of propofol relieve pruritus associated with liver disease. Gastroenterology 1993; 104(1): 244–7PubMed
123.
Borgeat A, Wilder-Smith OH, Saiah M, et al. Subhypnotic doses of propofol relieve pruritus induced by epidural and intrathecal morphine. Anesthesiology 1992; 76(4): 510–2PubMed
124.
Hanid MA, Levi AJ. Phototherapy for pruritus in primary biliary cirrhosis. Lancet 1980; 2(8193): 530PubMed
125.
Walt RP, Daneshmend TK, Fellows IW, et al. Effect of stanozolol on itching in primary biliary cirrhosis. Br Med J (Clin Res Ed) 1988; 296(6622): 607
126.
Lloyd-Thomas HGL, Sherlock S. Testosterone therapy for the pruritus of obstructive jaundice. BMJ 1952; 2: 1289–91PubMed
127.
Whitmore SE. Treatment of hepatobiliary pruritus. J Am Acad Dermatol 1997; 36 (2 Pt 1): 279PubMed
128.
Poupon R, Chretien Y, Poupon RE, et al. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1987; 1(8537): 834–6PubMed
129.
Matsuzaki Y, Tanaka N, Osuga T, et al. Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis. Am J Gastroenterol 1990; 85(1): 15–23PubMed
130.
Koeppel MC, Bramont C, Ceccaldi M, et al. Paroxysmal pruritus and multiple sclerosis. Br J Dermatol 1993; 129(5): 597–8PubMed
131.
Kimyai-Asadi A, Nousari HC, Kimyai-Asadi T, et al. Poststroke pruritus. Stroke 1999; 30(3): 692–3PubMed
132.
Osterman PO. Paroxysmal itching in multiple sclerosis. Br J Dermatol 1976; 95(5): 555–8PubMed
133.
Canavero S, Bonicalzi V, Massa-Micon B. Central neurogenic pruritus: a literature review. Acta Neurol Belg 1997; 97(4): 244–7PubMed
134.
Massey EW. Unilateral neurogenic pruritus following stroke. Stroke 1984; 15(5): 901–3PubMed
135.
Bernhard JD. Neurogenic pruritus and strange skin sensations. In: Bernhard JD, editor. Itch: mechanisms and management of pruritus. 1st ed. New York (NY): McGraw-Hill, 1994
136.
Zylicz Z, Smits C, Krajnik M. Paroxetine for pruritus in advanced cancer. J Pain Symptom Manage 1998; 16(2): 121–4PubMed
137.
Feuerman EJ. Sjogren’s syndrome presenting as recalcitrant generalized pruritus. Some remarks about its relation to collagen diseases and the connection of rheumatoid arthritis with the Sicca syndrome. Dermatologica 1968; 137(2): 74–86PubMed
138.
Kovacs SO, Kovacs SC. Dermatomyositis. J Am Acad Dermatol 1998; 39(6): 899–920PubMed
139.
Thaipisuttikul Y. Pruritic skin diseases in the elderly. J Dermatol 1998; 25(3): 153–7PubMed
140.
Jacobsen E, Billings JK, Frantz RA, et al. Age-related changes in sebaceous wax ester secretion rates in men and women. J Invest Dermatol 1985; 85(5): 483–5PubMed
141.
Yamamoto A, Serizawa S, Ito M, et al. Effect of aging on sebaceous gland activity and on the fatty acid composition of wax esters. J Invest Dermatol 1987; 89(5): 507–12PubMed
142.
Long CC, Marks R. Stratum corneum changes in patients with senile pruritus. J Am Acad Dermatol 1992; 27(4): 560–4PubMed
143.
Hunter JA. Seventh age itch. Br Med J (Clin Res Ed) 1985; 291(6499): 842
144.
Waisman M. A clinical look at the aging skin. Postgrad Med 1979; 66(1): 87–93, 96PubMed
145.
Bernhard JD. Phantom itch, pseudophantom itch, and senile pruritus. Int J Dermatol 1992; 31(12): 856–7PubMed
146.
Polenghi M, Colombo MD, Barcella ML, et al. A thioridazine-dihydroergotoxine combination in the treatment of senile pruritus [in Italian]. G Ital Dermatol Venereol 1989; 124(9): LI–LIIIPubMed
147.
Paul R, Jansen CT. Itch and malignancy prognosis in generalized pruritus: a 6-year follow-up of 125 patients. J Am Acad Dermatol 1987; 16(6): 1179–82PubMed
148.
Teofoli P, De Pita O, Frezzolini A, et al. Antipruritic effect of oral cyclosporin A in essential senile pruritus. Acta Derm Venereol 1998; 78(3): 232PubMed
149.
Ungvari G, Vladar K. Pimozide treatment for delusion of infestation. Act Nerv Super (Praha) 1986; 28(2): 103–7
150.
Munro A. Monosymptomatic hypochondriacal psychosis manifesting as delusions of parasitosis: a description of four cases successfully treated with pimozide. Arch Dermatol 1978; 114(6): 940–3PubMed
151.
Elmer KB, George RM, Peterson K. Therapeutic update: use of risperidone for the treatment of monosymptomatic hypochondriacal psychosis. J Am Acad Dermatol 2000; 43(4): 683–6PubMed
152.
Fawcett RG. Olanzapine for the treatment of monosymptomatic hypochondriacal psychosis. J Clin Psychiatry 2002; 63(2): 169PubMed
153.
Weintraub E, Robinson C. A case of monosymptomatic hypochondriacal psychosis treated with olanzapine. Ann Clin Psychiatry 2000; 12(4): 247–9PubMed
154.
Fried RG. Evaluation and treatment of “psychogenic” pruritus and self-excoriation. J Am Acad Dermatol 1994; 30(6): 993–9PubMed
Metadata
Title
Treatment of Pruritus Associated with Systemic Disorders in the Elderly
A Review of the Role of New Therapies
Authors
Dr Ann Lonsdale-Eccles
Andrew J. Carmichael
Publication date
01-03-2003
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 3/2003
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200320030-00004

Other articles of this Issue 3/2003

Drugs & Aging 3/2003 Go to the issue

Therapy in Practice

Treatment of Chronic Obstructive Pulmonary Disease in Older Patients

Current Opinion

Influenza Vaccination and Antiviral Therapy

Leading Article

Bisphosphonates to Prevent Osteoporosis in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

Review Article

Interventions to Improve Medication Compliance in Older Patients Living in the Community

Leading Article

Early Treatment of Benign Prostatic Hyperplasia
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits